true
{"AlternateComparison":false,"RelatedProducts":false,"Specification":true,"FeatureBenefit":false}
BD SurePath™ BD SurePath™ liquid-based Pap test

BD™ Density Reagent, 480 mL

Icon to close the modal
Support
Customer Care & Ordering
Phone Icon
866 979 9408, (905 288 6000 non toll free)
Modal Close Icon
Contact Us
Icon to close thank you modal
Thank you for contacting our sales team!
A sales representive will get in touch with you shortly.
Overview

The BD SurePath™ liquid-based Pap test provides advantages over conventional Pap smears and other liquid-based cytology (LBC) tests, resulting in greater disease detection.

true
Features and Benefits
Promotional Story
false
Specification

GTIN - each

00382904913328

1


Quantity - Each

1


Shelf Life (Days)

730

GTIN

GTIN - each 00382904913328 1

Packaging

Quantity - Each 1

Storage and Handling

Shelf Life (Days) 730
Electronic Instructions for Use (eIFUs)
Resources
Frequently Asked Questions
false
Related Products
RELATED PRODUCTS NOT AVAILABLE
Product Complaints
North American Regional Complaint Center
1-844-8BD-LIFE (1-844-823-5433)
Things to Consider

If you are a patient or end user, you can contact us yourself, or you may have your caregiver or your physician do that for you. To help us process your
information quickly and effectively, please contact our customer complaints
team.

To better facilitate our investigation, please include the following information in your reporting:


  • Product Name and/or Catalog Number
  • Lot Number or Serial Number
  • Any injuries and/or Harm?
  • What is the issue you experienced?
  • Is the actual sample or sample representative available? (If possible, please send affected sample)
  • Contact name and phone number
References
  • BD PrepStain™ slide processor: direct-to-vial study population [product insert]. Franklin Lakes, NJ: Becton, Dickinson and Company; 2016.
  • Fremont-Smith M, Marino J, Griffin B, Spencer L, Bolick D. Comparison of the Surepath liquid-based Papanicolaou smear with the conventional Papanicolaou smear in a multisite direct-to-vial study. Cancer. 102:269-279.
  • Nygård JF, Sauer T, Nygård M, Skare GB, Thoresen S Ø. CIN 2/3 and cervical cancer in an organised screening programme after an unsatisfactory or a normal Pap smear: a seven-year prospective study of the Norwegian population-based screening programme. J Med Screen. 2004;11(2):70-76.
  • Nance KV. Evolution of Pap testing at a community hospital: a ten year experience. Diagn Cytopathol. 2007:35(3):148-153.
true
true